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Purpose: The present study assessed the influence of L-DOPA administration on
neostriatal dopamine (DA) D2 receptor binding in relation to motor and exploratory
behaviors in the rat.
Methods: D2 receptor binding was measured in baseline, after challenge with the
aromatic L-amino acid decarboxylase inhibitor benserazide, and after challenge with
either 5 or 10mg/kg L-DOPA plus benserazide. Additional rats received injections of
saline. For baseline and challenges, striatal equilibrium ratios (V′′) were computed as3
estimation of the binding potential. Motor and exploratory behaviors were assessed for
30min in an open field prior to administration of [123I]IBZM. D2 receptor binding was
measured with small animal SPECT 2h after radioligand administration for 60min.
Results: Both L-DOPA doses significantly reduced D2 receptor binding relative to
baseline and led to significantly less ambulation, less head-shoulder motility, and more
sitting relative to saline. Moreover, 10mg/kg L-DOPA induced less head-shoulder motility,
more sitting, and more grooming than 5mg/kg L-DOPA. Analysis of time-behavior curves
showed that L-DOPA-treated animals relative to saline exhibited a faster rate of decrease
of ambulation frequency and a slower rate of decrease of both duration and frequency
of head-shoulder motility from a lower maximum level.
Conclusions: The reductions of striatal D2 receptor binding after L-DOPA may be
conceived to reflect elevated concentrations of synaptic DA. L-DOPA-treated animals
showed less ambulation and less head-shoulder motility than saline-treated animals,
indicating an association between less behavioral activity and increased availability of
striatal DA. The faster rate of decrease of ambulation frequency and the lower maximum
levels of both head-shoulder motility duration and frequency may be interpreted in terms
of influence of increased DA availability on behavioral habituation to a novel environment.
Keywords: D2 receptor, [
123I]IBZM, L-DOPA methylester, motor behavior, exploratory behavior, habituation,
time-behavior curves, small animal SPECT
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INTRODUCTION
Deficiencies of D2 receptor function are associated with a
variety of psychiatric conditions including anxiety disorder,
major depressive disorder, and schizophrenia (for reviews see
Nikolaus et al., 2010, 2012, 2014a) as well as numerous
neurological diseases such as M. Huntington, multiple system
atrophy, progressive supranuclear palsy, and late-stage idiopathic
Parkinson’s disease (PD, for review see Nikolaus et al., 2009).
Idiopathic PD may be effectively treated with the dopamine
(DA) precursor L-3,4-dihydroxyphenylalanine (L-DOPA; for
review see Okereke, 2002). Initially, the increased availability of
DA compensates for the decline of DA synthesis, DA storage,
and DA transporter (DAT) binding, which are characteristic
for idiopathic PD. With extended L-DOPA intake, however,
inhibitory feedback mechanisms exerted by presynaptic D2
receptor binding sites lead to a reduction of endogenous DA
formation, resulting in an aggravation of DAergic depletion.
Common features of long-term treatment with L-DOPA,
therefore, are dyskinesias and on-off and wearing-off phenomena
(for review see Cenci et al., 2011).
So far, there are four small animal imaging studies, which
assessed striatal D2 receptor binding after L-DOPA in healthy
(Opacka-Juffry et al., 1998) or 6-hydoxydopamine(6-OHDA)-
lesioned rats (Hume et al., 1995; Sossi et al., 2009; Sahin et al.,
2014). In healthy animals, challenge with 20 or 100mg/kg L-
DOPA plus 25mg/kg carbidopa led to a significant 40% increase
of striatal [11C]raclopride binding relative to untreated controls
(Opacka-Juffry et al., 1998). This effect was also observed
when the central amino acid decarboxylase (AADC) inhibitor
m-hydroxybenzylhydrazine (NSD-1015; 100mg/kg) was given
in addition to the peripheral AADC inhibitor carbidopa. It
was abolished, however, when chronic L-DOPA pre-treatment
(170mg/kg/day for 5 weeks) preceded the acute challenge.
In 6-OHDA-lesioned rats, challenge with 20mg/kg L-DOPA
plus 25mg/kg carbidopa and 100mg/kg NSD-1015 significantly
increased [11C]raclopride binding in the lesioned striatum
relative to the contralateral side and to unlesioned controls by 16
and 23%, respectively. However, also in the unlesioned striatum,
20mg/kg L-DOPA plus 25mg/kg carbidopa as well as 100mg/kg
NSD-1015 led to elevations of [11C]raclopride binding by 17 and
25%, respectively, relative to unlesioned controls (Hume et al.,
1995). This is contrasted by the findings of Sossi et al. (2009),
who observed a ≈5% reduction of [11C]raclopride binding
relative to baseline (significance not determined) in the lesioned
striatum after treatment with 50mg/kg L-DOPA plus 15mg/kg
benserazide. Similarly, Sahin et al. (2014) reported a 4% reduction
of [18F]fallypride binding relative to baseline in the lesioned
striatum after challenging 6-OHDA-lesioned rats under long-
term treatment with 6mg/kg/day L-DOPA plus 10mg/kg/day
benserazide for 4 weeks (withdrawal time: 2 days) with a single
dose of 12mg/kg L-DOPA (no reference to AADC inhibition). In
neither study was L-DOPA challenge found to reduce radioligand
binding relative to baseline in the contralateral striatum.
In rodents, L-DOPA is known to affect motor behaviors
dependent on the administed dose and the age of animals:
while lower doses (60–400mg/kg) have been found to decrease
motor activity, high doses (≥500mg/kg) lead to an enhancement
of motor activity (Boissier and Simon, 1966; Strömberg, 1970;
Bryson and Bischoff, 1971; Gronan, 1975). Moreover, an increase
of motor activity was observed in neonatal (5- to 8-day-old;
McDevitt and Setler, 1981) and immature (18- to 20-day-old) rats
(Grigoriadis et al., 1996) after doses of 12.5–50 and 150mg/kg,
respectively, whereas motor activity was decreased at 25–30 days
of age (Grigoriadis et al., 1996). In previous in vivo imaging
studies we have shown that L-DOPA doses of 5 and 10mg/kg
reduce [123I]FP-CIT binding to the striatal DA transporter (DAT)
and that decreases and increases of DAT binding may be related
to increases and decreases, respectively, of motor and exploratory
activity (Nikolaus et al., 2013, 2014b).
In the present study, we set out to complement these findings
by assessing the effect of 5 and 10mg/kg L-DOPA on behavior
and on D2 receptor binding in the rat striatum. In order to
allow comparisons between treatment groups, behavior, and D2
receptor binding was also assessed in saline-treated rats. D2
receptor binding data in baseline and after challenge with 5 and
10mg/kg L-DOPA was used to estimate DA release. Moreover,
temporal dynamics of behavior were assessed by fitting suitable
models to the acquired data and by statistically comparing time–
behavior (t–b) curves (Nikolaus et al., 2014b).
MATERIALS AND METHODS
Animals
The present study employed a total of 48 adult male Wistar
rats (ZETT, Heinrich-Heine University, Düsseldorf, Germany),
weighing 411 ± 43 g (mean ± SD). A total of 33 animals
underwent D2 receptor imaging studies in baseline, after
treatment with the aromatic AADC inhibitor benserazide
and/or after treatment with either 5 or 10mg/kg L-DOPA plus
benserazide. Motor and exploratory behaviors were assessed
contingent on adminsitration of either 5 or 10mg/kg L-
DOPA/benserazide (Figure 1). Five animals (5mg/kg L-DOPA:
n = 1; 10mg/kg L-DOPA: n = 4) merely underwent behavioral
measurements without imaging, since they dropped out after
administation of anesthesia. Sixteen further rats underwent
behavioral measurements and assessment of D2 receptor binding
after treatment with vehicle (0.9% saline). Also here, two animals
dropped out after administation of anesthesia, and, therefore,
merely underwent behavioral testing. Rats were maintained
in standard macrolon cages (590 × 380 × 200mm; three
animals per cage) in a climate cabinet (Scantainer, Scanbur BK,
Karslunde, Denmark; temperature, 20◦C; air humidity, 70%)
with an artificial ligh-dark cycle (lights on at 6:00 a.m., lights off
at 6:00 p.m.) and food and water freely available. The study was
approved by the regional authority and carried out in accordance
with the “Principles of laboratory animal care” (NIH publication
No. 86-23, revised 1985) and the German Law on the Protection
of Animals.
SPECT Camera
The small animal tomograph (“TierSPECT”) was described in
detail elsewhere (Schramm et al., 2000). For 123I, tomographic
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FIGURE 1 | Timeline of experimental procedure.
resolution and sensitivity amounted to 3.4mm and 16 cps/MBq,
respectively. A low-energy ultra-high-resolution parallel-hole
collimator (LEUHR, 37× 1× 0.2mm3) was mounted in front of
the detector head. Data were acquired in a 128× 128 matrix with
a pixel width and a slice thickness of ≈0.664mm, respectively.
Acquisition was conducted for 60min in a step-and-shoot mode
over a circular orbit in angular steps of 6◦ (60 projections, 60
s/projection). Data were reconstructed with an iterative ordered-
subset-expectation-maximization algorithm (three iterations,
four subsets/iteration). No post-filtering procedure was applied.
An attenuation correction of 0.11 cm−1 was implemented
assuming a uniformly attenuating medium.
D2 Receptor Imaging Studies
D2 receptor binding was assessed in baseline, after benserazide
(Sigma-Aldrich, Taufkirchen, Germany; dose: 10mg/kg,
concentration: 10mg/ml), after L-DOPA methylester (Sigma-
Aldrich, Taufkirchen, Germany; dose: 5 and 10mg/kg,
concentrations: 5 and 10mg/ml) plus benserazide (dose,
10mg/kg; concentration, 10mg/ml) and after vehicle (0.9%
saline; B. Braun Melsungen AG, Melsungen, Germany; dose:
1ml/kg). Benserazide is a peripherally-acting AADC inhibitor,
which is applied in order to prevent the metabolisation of
L-DOPA before it passes the blood-brain barrier (Shen et al.,
2003).
Since maximum striatal DA concentrations are reached
40min after i.p. L-DOPA and remain stable for ∼2 h
(e.g., de Souza Silva et al., 1997), challenges were applied
intraperitoneally (i.p.) 30min prior to radioligand application
and 75min prior to the beginning of SPECT acquisition. L-
DOPA and benserazide were administed simultaneously, since
pre-treatment with benserazide up to 3 h prior to L-DOPA
administration did not alter motor responses to L-DOPA
compared to simultaneous application of both compounds
(Tayarani-Binazir et al., 2010). Thirty minutes after benserazide,
L-DOPA/benserazide, or saline, animals received i.p. injections
of 0.9ml/kg ketaminehydrochloride (Ketavet R©, Pharmacia
GmbH, Erlangen, Germany; concentration: 100mg/ml) and
0.4ml/kg xylazinehydrochloride (Rompun R© Bayer, Leverkusen,
Germany; concentration: 2%). Then 26 ± 4 MBq [123I]IBZM
(GE Healthcare, München, Germany; concentration: 3.4 × 10−9
g/ml, specific activity: >74 TBq/mmol at reference time) were
injected into the lateral tail vein using a winged infusion needle
set. The tube was rinsed with 1ml 0.9% saline amounting to a
total injection volume of 1.3ml.
Since previous studies on both humans and rats had shown
that specific binding of [123I]IBZM in the striatum reaches a
plateau at about 40min post-injection, which remains stable
for up to 2 h (Verhoeff et al., 1991; Seibyl et al., 1992), SPECT
measurements of D2 receptor binding were started 45min after
radioligand administration. Since SPECT measurements were
conducted over 1 h, animals were kept under anesthesia for a total
of 105min.
Behavioral Studies
Immediately after the injection of 5 or 10mg/kg L-DOPA or
saline, rats were placed into the center of a cage with a topunit
equipped with light-emitting diodes and a charge-coupled device
(CCD) camera (Phenotyper R©, Noldus Information Technology,
Wageningen, The Netherlands; open field dimensions: 45 ×
45 × 56 cm). Durations (s) and frequencies (n) of motor and
exploratory behaviors were rated blindly in blocks of 5min for
a total of 30min using EthoVision XT (Noldus Information
Technology, Wageningen, The Netherlands). Rated behaviors
were: (A) ambulation as a measure of motor activity; (B) sitting
as a measure of “passive immobility” according to Müller et al.
(2004); (C) rearing (freely standing or leaning against the wall)
as a measure of both motor activity and non-selective attention
according to Aspide et al. (1998); (D) head-shoulder motility as
a parameter of both motor activity and non-selective attention
(Nikolaus et al., 2013, 2014b); (E) grooming (fur, paw and claw
licking, scratching). In addition, based on the dislocation of the
animal’s center point, EthoVision XT automatically determined
the distance in centimeters traveled by the rat. Following the
behavioral trials, animals were anesthetized and administered
[123I]IBZM as described above.
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Evaluation of D2 Receptor Imaging Studies
Imaging data were evaluated using PMOD (version 3.5, PMOD
Technologies Ltd., Zürich, Switzerland). Maximum striatal count
rates (counts/pixel) were determined on coronal slices by
defining a spherical region of interest (ROI; radius: 4mm,
volume: 0.16 cm3), which comprised a total of 6 pixels. On the
same slices, cerebellar count rates (counts/pixel) were obtained
by defining an ellipsoid reference region (REF; radius: 8mm,
volume: 0.35 cm3), which comprised a total of 13 pixels and was
situated ∼15mm posterior to the frontal cortex corresponding
anatomically to the rat cerebellum. Left and right striatal counts
rates were averaged. The equilibrium ratios of the distribution
volumes of the specifically and the non-specifically bound
compartment [V′′3 = VT(ROI)/VT(REF) − 1] were computed as
estimates for the binding potentials (Laruelle et al., 1994).
Statistical Analysis
D2 Receptor Imaging Studies
Distributions of binding data were tested for normality with
the non-parametric Kolmogorov–Smirnov test (α = 0.05). In
each pre-treatment condition (baseline, saline, benserazide, 5
and 10mg/kg L-DOPA/benserazide), V′′3-values were found to
be normally distributed (0.09 ≤ p ≤ 0.20). Cerebellar
count rates were not normally distributed in all pre-treatment
conditions (0.0001 ≤ p ≤ 0.20). Therefore, striatal V′′3-
values and cerebellar radioactivity count rates were compared
between pre-treatment conditions (baseline, benserazide, 5 and
10mg/kg L-DOPA/benserazide) by paired t-test (two-tailed, α =
0.0167 after Bonferroni correction for multiple comparisons)
and the Wilcoxon signed rank test for paired samples (two-
tailed, α = 0.0167 after Bonferroni correction), respectively.
In addition, striatal V′′3-values and cerebellar radioactivity count
rates were compared between treatment groups (5 and 10mg/kg
L-DOPA/benserazide, saline) with the t-test for independent
samples (two-sided, α = 0.0167 after Bonferroni correction)
and the Kruskal Wallis test for unrelated samples (two-tailed,
α = 0.0167 after Bonferroni correction), respectively.
DA release is generally assessed in vivo by double
measurement of D2 receptor binding—one time prior to
and one time contingent on the administration of compounds,
which lead to the increased availability of DA in the synaptic
cleft (for review see Laruelle, 2000). The principle underlying
this approach is the competition between endogenous DA and
the administered D2 receptor radioligand The dissociation
constant, KD, of the endogenous ligand DA is 7.5 nM (for review
see Seeman and Grigoriadis, 1987), whereas for the exogenous
ligand IBZM KD’s of 0.28 (Verhoeff et al., 1991) and 1.2 nM (de
Paulis et al., 1988) were reported (mean KD, 0.74 nM). As the
affinity, K, is defined as the reciprocal of the KD, the affinities
of endogenous and exogenous ligand, Kendo and Kexo, amount
to 0.13 and 1.35 nM−1, respectively. In order to estimate the
change of synaptic DA concentrations induced by the individual
doses of L-DOPA, for each animal the percentual difference
of [123I]IBZM binding relative to baseline was computed and
multiplied with the ratio of affinities (Kexo/Kendo). Percentual
reductions of radioligand binding relative to baseline (and
estimated alterations of DA levels) were compared between 5 and
10mg/kg L-DOPA/benserazide with the parametric independent
t-test for unrelated samples (two-sided, α = 0.05).
Calculations were performed using IBM SPSS Statistics 22
(IBM SPSS Software Germany, Ehningen, Germany).
Behavioral Studies
Distributions of behavioral data [traveled distance (cm), duration
(s) and frequency (n) of ambulation, sitting, rearing, head-
shoulder motility, and grooming in 5-min bins were assessed
with the non-parametric Kolmogorov–Smirnov test (α = 0.05)].
Since the majority of behavioral parameters was not found to
be normally distributed in any of the pre-treatment conditions
(0.0001 ≤ p ≤ 0.2), behaviors in each 5-min time bin and over
the whole trial (min 1–30) were compared between groups using
theMann–WhitneyU-test for unrelated samples (two-sided, α =
0.0167 after Bonferroni correction). Calculations were performed
using IBM SPSS Statistics 22.
The medians of the individual behavioral parameters
obtained after saline (Y-axis: traveled distance, duration,
and frequency of ambulation, sitting, rearing, head-shoulder
motility, or grooming) were plotted against the end-points of
the individual time frames (X-axis). Upon visual inspection
of the data, the following mathematical models were fit to
the individual behavioral parameters, using either linear or
non-linear regression analysis with the regression coefficient
(R2) as a measure for the goodness of fit: (1) traveled distance:
exponential function [y(t) = a ∗ exp (−K ∗ x) + plateau with
a, value at the time t; K, rate constant; t, time); R2 = 0.953;
(2) ambulation duration: exponential function; R2 = 0.982; (3)
ambulation frequency: exponential function; R2 = 0.964; (4)
sitting duration: linear function (y = ax + b with a, slope and b,
y-intercept); R2 = 0.920; (5) sitting frequency: quadratic function
(y = a + bx + cx2 with a, absolute term; bx, linear term; cx2,
quadratic term); R2 = 0.965; (6) rearing duration: exponential
function; R2 = 0.877; (7) rearing frequency: exponential function;
R2 = 0.933; (8) duration of head-shoulder motility: quadratic
function; R2 = 0.966; (9) frequency of head-shoulder motility:
linear function; R2 = 0.931).
The same models were fit to the behavioral data obtained
after 5 and 10mg/kg L-DOPA with R2-values, respectively, of
0.980 and 0.991 (traveled distance), 0.967 and 0.979 (ambulation
duration), 0.966 and 0.997 (ambulation frequency), 0.945 and
0.958 (sitting duration), 0.682 and 0.767 (sitting frequency),
0.930 and 0.877 (rearing duration), 0.966 and 0.980 (rearing
frequency), 0.979 and 0.958 (duration of head-shoulder motility),
and 0.820 and 0.877 (frequency of head-shoulder motility). Due
to the low expression of both grooming duration and grooming
frequency, the grooming data could not be reasonably fit to
any mathematical model. Curve fittings were performed using
GraphPad Prism (version 3.0 for Windows, GraphPad Software,
San Diego, USA). t–b Curves were compared between treatment
groups using the F-test (α = 0.0167 after Bonferroni correction).
In order to gauge the extent of association between D2 receptor
binding and motor/exploratory parameters, Spearman rank
correlation coefficients (r) were computed (α = 0.05) for
V3
′′-values and behavioral data in min 1–5, 6–10, 11–15,
16–20, 21–25, 26–30, and 1–30. Calculations were performed
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using SigmaStat for Windows Version 3.5 (Systat Software Inc.,
Erkrath, Germany).
RESULTS
D2 Receptor Imaging Studies
Figures 2A, 3A show characteristic images of [123I]IBZM
accumulation on coronal slices in baseline and after challenge
with 5 and 10mg/kg L-DOPA/benserazide and benserazide
alone. Striatal [123I]IBZM accumulations are markedly reduced
following pre-treatment with both 5mg/kg (Figure 2A) and
10mg/kg L-DOPA/benserazide (Figure 3A). SPECT images
were obtained on the same rats. Figure 4A shows characteristic
images of [123I]IBZM accumulations on coronal slices of
different rats after treatment with saline and 5 and 10mg/kg
L-DOPA/benserazide and 10mg/kg L-DOPA/benserazide.
Again, striatal [123I]IBZM accumulations were lower following
challenge with both 5 and 10mg/kg L-DOPA/benserazide.
After application of 5mg/kg (Figure 2B) and 10mg/kg
L-DOPA/benserazide (Figure 3B), striatal V′′3-values were 2.06±
0.63 (mean ± SD) and 1.68 ± 0.66, respectively. Baseline
V′′3 amounted to 2.86 ± 0.64 (5mg/kg L-DOPA/benserazide)
and 2.17 ± 0.69 (10mg/kg L-DOPA/benserazide), while,
after benserazide, V′′3-values of 2.69 ± 0.63 (5mg/kg
L-DOPA/benserazide) and 1.85 ± 0.84 (10mg/kg L-
DOPA/benserazide) were obtained. The comparison of baseline
and 5mg/kg L-DOPA/benserazide yielded no significant
difference after Bonferroni correction (p = 0.038). Likewise,
differences between baseline and benserazide (p = 0.523)
and between 5mg/kg L-DOPA/benserazide and benserazide
(p = 0.073) were not significant. Comparison between baseline
and 10mg/kg L-DOPA/benserazide yielded a p = 0.001. The
differences between baseline and benserazide (p = 0.916)
and between 10mg/kg L-DOPA/benserazide and benserazide
(p = 0.198) were not significant.
After saline, striatal V′′3 was 2.63 ± 0.78 (Figure 4B).
Comparisons between saline and 5mg/kg L-DOPA/benserazide,
between saline and 10mg/kg L-DOPA/benserazide as well as
between 5 and 10mg/kg L-DOPA/benserazide yielded p-values
of 0.063, 0.002, and 0.166, respectively.
Alterations of D2 receptor binding relative to baseline
amounted to 79 ± 35% after 5mg/kg L-DOPA/benserazide
and to 81 ± 15% after 10mg/kg L-DOPA/benserazide.
Multiplication of percentual decreases by Kexo/Kendo yielded
mean increases of synaptic DA by 827 ± 361% after 5mg/kg
L-DOPA/benserazide and by 840 ± 161% after 10mg/kg
L-DOPA/benserazide. Comparison between groups yielded a
p = 0.907.
After 5 and 10mg/kg L-DOPA/benserazide, median cerebellar
radioactivity concentrations amounted to 585 counts/pixel (25-
percentile: 512 counts/pixel, 75-percentile: 689 counts/pixel)
and 689 counts/pixel (25-percentile: 557 counts/pixel, 75-
percentile: 798 counts/pixel), respectively. In baseline, median
cerebellar count rates were 551 counts/pixel (25-percentile:
512 counts/pixel, 75-percentile: 624 counts/pixel) and 532
counts/pixel (25-percentile: 512 counts/pixel, 75-percentile: 853
counts/pixel), while after benserazide, cerebellar radioactivity
FIGURE 2 | (A) Coronal [123 I]IBZM images of the samt rat in baseline and after challenge with 5mg/kg L-DOPA/benserazide and benserazide alone. All images show
V′′3-values; it is understood, that the calculation of V
′′
3 is only valid for regions with specific radioligand binding such as the rat striatum. Calculations were performed
using PMOD (version 3.5, PMOD Technologies Ltd., Zürich, Switzerland). (B) Striatal equilibrium ratios (V′′3) in baseline and after challenge with 5mg/kg
L-DOPA/benserazide and benserazide alone. Rendered are means and standard deviations of the means. The circles represent the individual animals. For significant
differences between conditions the respective p-values are given (two-tailed paired t-test, α = 0.0167 after Bonferroni correction). If the outlier in the benserazide
condition (Figure 2B) was excluded, comparison of 5mg/kg L-DOPA/benserazide and benserazide yielded a p of 0.123.
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FIGURE 3 | (A) Coronal [123 I]IBZM images of the samt rat in baseline and after challenge with 10mg/kg L-DOPA/benserazide and benserazide alone. All images
show V′′3-values; it is understood, that the calculation of V
′′
3 is only valid for regions with specific radioligand binding such as the rat striatum. Calculations were
performed using PMOD (version 3.5, PMOD Technologies Ltd., Zürich, Switzerland). (B) Striatal equilibrium ratios (V′′3) in baseline and after challenge with 10mg/kg
L-DOPA/benserazide and benserazide alone. Rendered are means and standard deviations of the means. The circles represent the individual animals. For significant
differences between conditions the respective p-values are given (two-tailed paired t-test, α = 0.0167 after Bonferroni correction).
FIGURE 4 | (A) Coronal [123 I]IBZM images of different rats after challenge with saline, 5 and 10mg/kg L-DOPA/benserazide. All images show V′′3 values; it is
understood, that the calculation of V ′′3 is only valid for regions with specific radioligand binding such as the rat striatum. Calculations were performed using PMOD
(version 3.5, PMOD Technologies Ltd., Zürich, Switzerland). (B) Striatal equilibrium ratios (V′′3) after challenge with saline, 5 and 10mg/kg L-DOPA/benserazide.
Rendered are means and standard deviations of the means. The circles represent the individual animals. For significant between-group differences the respective
p-values are given (two-tailed independent t-test, α = 0.0167 after Bonferroni correction).
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concentrations amounted to 512 counts/pixel (25-percentile:
473 counts/pixel, 75-percentile: 591 counts/pixel) and 768
counts/pixel (25-percentile: 532 counts/pixel, 75-percentile: 811
counts/pixel) in the 5 and 10mg/kg L-DOPA/benserazide
condition, respectively. No significant differences were found
between treatment conditions (0.123 ≤ p ≤ 0.859).
After saline, median cerebellar radioactivity concentrations
were 627 counts/pixel (25-percentile: 527 counts/pixel, 75-
percentile: 694 counts/pixel). No significant between-group
differences were obtained (p = 0.255).
Behavioral Studies
Median Differences and t–b Curves–Traveled
Distance
Comparison of traveled distance between animals treated with
10mg/kg L-DOPA/benserazide and saline and between animals
treated with 5 and 10mg/kg L-DOPA/benserazide yielded no
significant difference in any of the time bins (0.062 ≤ p ≤
1.0; Figure 5). Also the median traveled distance in min 26–30
after 5mg/kg L-DOPA/benserazide was not significantly different
from saline (p = 0.032) after Bonferroni correction.
t–b Curves neither differed significantly between 5mg/kg
L-DOPA/benserazide and saline (p = 0.319) nor between 5
and 10mg/kg L-DOPA/benserazide (p = 0.089). Comparison
of t–b curves after 10mg/kg L-DOPA/benserazide (a, 4065 ±
232; K, 0.069 ± 0.017; plateau, −403.9 ± 341.5) and saline
(a, 5016 ± 929; K, 0.108 ± 0.045; plateau, 402.9 ± 439)
yielded no significant difference after Bonferroni correction (p =
0.038). Nevertheless, both curve plateau and rate constant after
10mg/kg L-DOPA/benserazide were lower compared to saline.
This suggests that after the higher L-DOPA dose, the traveled
distance decreased at a slower rate to a lower final level relative
to control.
Ambulation
Ambulation duration neither differed signficantly between
animals treated with 10mg/kg L-DOPA/benserazide
and saline nor between animals treated with 5 and
10mg/kg L-DOPA/benserazide in any of the time bins
(0.220 ≤ p ≤ 0.9432; Figure 6A). Likewise, after Bonferroni
correction, the median duration of ambulation in min 26–
30 after 5mg/kg L-DOPA/benserazide was not significantly
different from the median duration of ambulation after
saline (p = 0.05).
Comparison of t–b curves yielded no significant difference
(0.155 ≤ p ≤ 0.551).
FIGURE 5 | Traveled distance (cm) after vehicle (0.9% saline), 5 and 10mg/kg L-DOPA. The figure shows box and whisker plots of median distances traveled
during the whole time of testing (gray shade) and in the individual 5-min time bins. 25-/75-percentiles are given in the boxes, while 5-/95-percentiles are represented
by the whiskers. The circles represent the individual animals. For significant between-group differences the respective p-values are given (two-tailed Mann–Whitney
U-test, α =0.0167 after Bonferroni correction). Inset: t–b Curves obtained by plotting median values of traveled distances against time and fitting exponential functions
[y(t) = a * exp (−K * x) + plateau with a, value at the time t; -K, rate constant; t, time] to these data. For the comparisons between groups (two-tailed F-test, α =
0.0167 after Bonferroni correction) the respective p-values are given).
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FIGURE 6 | Ambulation. (A) Duration (s) and (B) frequency (n) after vehicle (0.9% saline), 5 and 10mg/kg L-DOPA. The figure shows box and whisker plots of median
ambulation durations and frequencies during the whole time of testing (gray shade) and in the individual 5-min time bins. 25-/75-percentiles are given in the boxes,
while 5-/95-percentiles are represented by the whiskers. The circles represent the individual animals. For significant between-group differences the respective p-values
are given (two-tailed Mann–Whitney U-test, α = 0.0167 after Bonferroni correction). Insets: t–b Curves obtained by plotting median values of ambulation durations (A)
and ambulation frequencies (B) against time and fitting exponential functions [y(t)= a * exp (−K * x) + plateau with a, value at the time t; -K, rate constant; t, time] to
these data. For the comparisons between treatment groups (two-tailed F-test, α = 0.0167 after Bonferroni correction) the respective p-values are given.
Rats treated with 5mg/kg L-DOPA/benserazide displayed a
significantly lower ambulation frequency (Figure 6B) compared
to saline in min 1–5 (p = 0.017). Comparison of ambulation
frequency after 5mg/kg L-DOPA/benserazide and saline in
min 26–30 yielded no significant difference after Bonferroni
correction (p = 0.045). After 10mg/kg L-DOPA/benserazide,
animals moved significantly less frequently compared to saline
in min 1–5 and 6–10 as well as during the whole testing
time (0.0001 ≤ p ≤ 0.004). There were no differences between
10mg/kg L-DOPA/benserazide and saline in min 11–15 after
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Bonferroni correction (p = 0.019). Significant between-group
differences were evident starting with the first time frame.
t–b Curves differed significantly between 10mg/kg L-
DOPA/benserazide (exponential fit; a, 42.51 ± 2.38; K, 0.14 ±
0.01; plateau, 2.82 ± 0.56) and saline (a, 63.96 ± 9.68; K,
0.10 ± 0.04; plateau, 2.61 ± 5.34; p = 0.003) as well
as between 10 and 5mg/kg L-DOPA/benserazide (a, 66.49 ±
9.73; K, 0.10 ± 0.04; plateau, 6.79 ± 5.39; p = 0.013).
After 10mg/kg L-DOPA/benserazide, the rate constant was
lower compared to saline. This suggests that after 10mg/kg L-
DOPA/benserazide, ambulatory frequency decreased at a faster
rate. After 10mg/kg L-DOPA/benserazide, however, both rate
constant and plateau were higher compared to 5mg/kg L-
DOPA/benserazide indicating a faster rate of increase to a higher
final level.
Sitting
After 5mg/kg L-DOPA/benserazide, animals displayed
significantly longer sitting behavior (Figure 7A) in min
6–10 (p = 0.009) compared to rats treated with saline. After
10mg/kg L-DOPA/benserazide, rats sat for a significantly longer
time than in the saline condition in min 1–5 (p = 0.010) as well
as throughout the whole trial (p = 0.015). Comparison between
10mg/kg L-DOPA/benserazide and saline in min 25–30 yielded
no significant difference after Bonferroni correction (p = 0.034).
Significant between-group differences were evident from the first
time frame, but temporarily disappeared during the third to fifth
time frame (min 11–25).
t–b Curves did not differ between 5mg/kg L-
DOPA/benserazide and saline (p = 0.359). Likewise, comparison
of t–b curves after 10mg/kg L-DOPA/benserazide (linear fit;
slope, 6.15 ± 0.64; y-intercept, 14.80 ± 12.6) and saline (slope,
6.57 ± 1.12; y-intercept, −26.84 ± 20.32; p = 0.037) as well
as after 10 and 5mg/kg L-DOPA/benserazide (slope, 8.69 ±
0.96; y-intercept, −55.67 ± 18.66; p = 0.027) yielded no
significant difference after Bonferroni correction. Nevertheless,
the slope of the 5mg/kg curve exceeded the slopes of the
saline and the 10mg/kg curve, indicating a faster rate of
increase of sitting duration to a higher final level after the lower
L-DOPA dose.
Comparison of sitting frequency (Figure 7B) between
10mg/kg L-DOPA/benserazide and saline in min 1–5
(p = 0.034) and between 5 and 10mg/kg L-DOPA/benserazide
in min 6–10 (p = 0.038) yielded no significant difference
after Bonferroni correction. Moreover, no significant difference
was found between 5mg/kg L-DOPA/benserazide and saline
(0.083 ≤ p ≤ 0.948).
Comparisons of t–b curves after 10mg/kg L-
DOPA/benserazide (quadratic fit; a, 7.50 ± 1.52; b, 0.16 ±
0.20; c, −0.01 ± 0.006) and saline (a, −2.28 ± 1.84; b, 1.36 ±
0.26; c, −0.04 ± 0.007; p = 0.04) as well as after 5 (a, 0.87
± 2.16; b, 0.54 ± 0.28; c, −0.01 ± 0.01; p = 0.04) and
10mg/kg L-DOPA/benserazide yielded no significant difference
after Bonferroni correction. Still, after 5 and 10mg/kg L-
DOPA/benserazide, the linear term was lower and the quadratic
term was higher compared to saline suggesting a slower rate of
increase of sitting frequency to a higher final level.
Rearing
Duration of rearing neither differed signficantly between
animals treated with 10mg/kg L-DOPA/benserazide and
saline nor between animals treated with 5 and 10mg/kg L-
DOPA/benserazide in any of the time bins (0.142 ≤ p ≤ 1.0;
Figure 8A). Moreover, comparison of rearing duration between
5mg/kg L-DOPA/benserazide and saline in min 26–30 yielded a
p-value (p = 0.025), which was not significant after Bonferroni
correction.
Likewise, comparison of t–b curves yielded no significant
differences (0.127 ≤ p ≤ 0.752).
Rearing frequency did not differ significantly between
animals treated with 10mg/kg L-DOPA/benserazide and
saline and between animals treated with 5 and 10mg/kg
L-DOPA/benserazide (0.058 ≤ p ≤ 0.843; Figure 8B).
Furthermore, comparison of rearing frequency between 5mg/kg
L-DOPA/benserazide and saline in min 26–30 yielded no
significant difference after Bonferroni correction (p = 0.032).
t–b Curves differed significantly between 5 (exponential fit;
a, 91.11 ± 19.37; K, 0.10 ± 0.05; plateau, −5.95 ± 11.02)
and 10mg/kg L-DOPA benserazide (a, 95.45 ± 54.29; K, 0.04
± 0.06; plateau, −30.37 ± 70.11; p = 0.004). The higher
rate constant after 5mg/kg L-DOPA/benserazide suggested a
higher rate of decrease of rearing frequency, while the higher
plateau value indicated a higher final level of rearing frequency
compared to the higher L-DOPA dose. The difference of t–b
curves after 10mg/kg L-DOPA and saline (a, 71.03 ± 15.36;
K, 0.073 ± 0.067; plateau, −2.11 ± 21.08; p = 0.026) was
not significant after Bonferroni correction. Yet, the lower rate
constant after 10mg/kg L-DOPA/benserazide implied a (slightly)
lower rate of decrease of rearing frequency, while the lower
plateau value indicated a lower final level of rearing frequency
compared to saline.
Head-Shoulder Motility
After treatment with 5mg/kg L-DOPA/benserazide, the duration
of head-shoulder motility (Figure 9A) was significantly shorter
relative to saline in min 11–15 (p = 0.009), 16–20 (p = 0.003),
and 26–30 (p = 0.013) as well as throughout the whole trial (p =
0.001). However, there was no significant difference in min 6–10
after Bonferroni correction (p = 0.05). Head-shoulder motility
was significantly shorter after 10mg/kg L-DOPA/benserazide
relative to saline in min 6–10 and 26–30 as well as throughout
the whole trial (0.004 ≤ p ≤ 0.008). Significant between-group
differences were evident from min 6.
t–b Curves differed significantly between 5mg/kg L-
DOPA/benserazide (quadratic fit; a, 110.30 ± 10.74; b,
−1.85 ± 1.41; c; −0.030 ± 0.039) and saline (a, 112.50 ±
8.00; b, 0.02 ± 1.05; c; −0.05 ± 0.03; p = 0.0005). However,
no significant difference was obtained between t–b curves after
10mg/kg L-DOPA/benserazide (a, 98.31 ± 14.41; b, −0.88 ±
1.86; c; −0.03 ± 0.05; p = 0.031) and saline after Bonferroni
correction. Moreover, there was no difference between 5 and
10mg/kg L-DOPA/benserazide (p = 0.257). Notably, after
both L-DOPA doses, linear and quadratic terms were lower
relative to saline suggesting a slower rate of decrease from a lower
maximum level after L-DOPA.
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FIGURE 7 | Sitting. (A) Duration (s) and (B) frequency (n) after vehicle (0.9% saline), 5 and 10mg/kg L-DOPA. The figure shows box and whisker plots of median
sitting durations and frequencies during the whole time of testing (gray shade) and in the individual 5-min time bins. 25-/75-percentiles are given in the boxes, while
5-/95-percentiles are represented by the whiskers. The circles represent the individual animals. For significant between-group differences the respective p-values are
given (two-tailed Mann–Whitney U-test, α = 0.0167 after Bonferroni correction). Insets: t–b Curves obtained by plotting median values of sitting durations (A) and
sitting frequencies (B) against time. Linear functions (y = ax + b with a, slope and b, y-intercept) were fitted to the plots of sitting durations, whereas quadratic
functions (y = a + bx + cx2 with a, absolute term; bx, linear term; cx2, quadratic term) were fitted to the plots of sitting frequencies. For the comparisons between
treatment groups (two-tailed F-test, α = 0.0167 after Bonferroni correction) the respective p-values are given.
Rats treated with 5mg/kg L-DOPA/benserazide moved their
head and shoulders (Figure 9B) significantly less frequently in
min 6–11, 11–15, 16–20, and 26–30 as well as throughout the
whole trial (0.001 ≤ p ≤ 0.013). After treatment with 10mg/kg
L-DOPA/benserazide, the median frequency of head-shoulder
motility was decreased relative to saline in min 1–5, 6–10, 11–15,
and 26–30 as well as during the whole testing time (0.0001≤ p≤
0.009). The frequency of head-shoulder motility was significantly
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FIGURE 8 | Rearing. (A) Duration (s) and (B) frequency (n) after vehicle (0.9% saline), 5 and 10mg/kg L-DOPA. The figure shows box and whisker plots of median
rearing durations and frequencies during the whole time of testing (gray shade) and in the individual 5-min time bins. 25-/75-percentiles are given in the boxes, while
5-/95-percentiles are represented by the whiskers. The circles represent the individual animals. For significant between-group differences the respective p-values are
given (two-tailed Mann–Whitney U-test, α = 0.0167 after Bonferroni correction). Insets: t–b Curves obtained by plotting median values of rearing durations (A) and
rearing frequencies (B) against time and fitting exponential functions [y(t)= a * exp (−K * x) + plateau with a, value at the time t; -K, rate constant; t, time] to these data.
For the comparisons between treatment groups (two-tailed F-test, α = 0.0167 after Bonferroni correction) the respective p-values are given.
elevated after 5 relative to 10mg/kg L-DOPA/benserazide in
min 1–6 (p = 0.003). Comparisons between 10mg/kg L-
DOPA/benserazide and saline in min 16–20 as well as between
5 and 10mg/kg L-DOPA/benserazide in min 1–30 yieled no
significant difference after Bonferroni correction (p = 0.052,
each). Significant between-group differences were evident from
the first time frame on, but temporarily disappeared during the
fifth time frame (min 21–25).
t–b Curves differed significantly between 10mg/kg L-
DOPA/benserazide (linear fit; slope, −0.46 ± 0.09; y-intercept,
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FIGURE 9 | Head-shoulder motility. (A) Duration (s) and (B) frequency (n) after vehicle (0.9% saline), 5 and 10mg/kg L-DOPA. The figure shows box and whisker
plots of median durations and frequencies of head-shoulder motility during the whole time of testing (gray shade) and in the individual 5-min time bins.
5-/75-percentiles are given in the boxes, while 5-/95-percentiles are represented by the whiskers. The circles represent the individual animals. For significant
between-group differences the respective p-values are given (two-tailed Mann–Whitney U-test, α = 0.0167 after Bonferroni correction). Insets: t–b Curves obtained by
plotting median values of motility durations (A) and frequencies (B) against time. Quadratic functions (y = a + bx + cx2 with a, absolute term; bx, linear term; cx2,
quadratic term) were fitted to the plots of motility durations, while linear functions (y = ax + b with a, slope and b, y-intercept) were fitted to the plots of motility
frequencies. For the comparisons between grousp (two-tailed F-test, α = 0.0167 after Bonferroni correction) the respective p-values are given.
23.93 ± 1.69) and saline (slope, −1.12 ± 0.15; y-intercept,
46.93 ± 2.96; p < 0.0001). No difference was obtained
between 5 and 10mg/kg L-DOPA/benserazide (p = 0.088).
Likewise, curves after 5mg/kg L-DOPA/benserazide (slope,
−1.09 ± 0.03; y-intercept, 37.78 ± 5.35) and saline were not
different after Bonferroni correction (p = 0.043). Slopes
as well as y-intercepts were lower after both L-DOPA doses
relative to saline, indicating that the frequency of head and
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shoulder motility decreased at a slower rate from a lower
maximum level.
Grooming
Comparison of grooming duration between animals treated with
10mg/kg L-DOPA/benserazide and saline yielded no significant
difference in any of the time bins (0.131 ≤ p ≤ 0.984; data
not shown). Likewise, after Bonferroni correction, grooming
duration did not differ between 5mg/kg L-DOPA/benserazide
and saline during the whole trial (p = 0.04). Yet, rats groomed
for a significantly longer time after 5mg/kg L-DOPA/benserazide
relative to saline in min 6–10 (p < 0.0001). Moreover, grooming
duration was longer in animals treated with 5mg/kg compared to
animals treated with 10mg/kg L-DOPA/benserazide in min 6–10
(p ≤ 0.0001) as well as throughout the whole trial (p = 0.001).
Comparison of grooming frequency between 5mg/kg L-
DOPA/benserazide and saline as well as between 10mg/kg L-
DOPA/benserazide and saline yielded no significant difference in
any of the time bins (0.085 ≤ p ≤ 0.918; data not shown). After
5mg/kg L-DOPA/benserazide, rats groomed with a significantly
higher frequency relative to 10mg/kg L-DOPA/benserazide in
min 6–10 (p = 0.007) as well as throughout the whole testing
time (p = 0.001).
Correlation of Motor/Exploratory
Behaviors with D2 Receptor Binding
After 5mg/kg L-DOPA/benserazide, D2 receptor binding
correlated negatively with sitting frequency in min 21–25 (r = –
0.596, p = 0.047). A marginal positive correlation was obtained
between D2 receptor binding and rearing frequency in min
26–30 (r = 0.547, p = 0.076).
After 10mg/kg L-DOPA/benserazide, D2 receptor binding
correlated positively with sitting duration inmin 25–30 (r =0.714,
p = 0.037), with the frequency of head-shoulder motility in min
1–30 (r = 0.683, p = 0.036), and with grooming frequency in min
11–15 (r = 0.795, p = 0.01) and min 1–30 (r = 0.647, p =
0.030). Marginal positive correlations were obtained between D2
receptor binding and rearing frequency in min 1–5 (r = 0.635,
p = 0.072) and the duration of head-shoulder motility in min 6–
10 (r = 0.635, p = 0.072), while a marginal negative correlation
was found between D2 receptor binding and rearing frequency in
min 26–30 (r = 0.635, p = 0.059).
No significant correlations with behavioral parameters were
observed after saline (0.231 ≤ p ≤ 0.976).
DISCUSSION
D2 Receptor Binding
Challenge with both 5 and 10mg/kg L-DOPA/benserazide
reduced D2 receptor binding relative to baseline and saline. In
each case, however, only the high dose challenge had a significant
effect after Bonferroni correction. Cerebellar radioactivity
concentrations were not significantly influenced by L-DOPA
challenges indicating that no confounding effects were exerted
on radioligand accumulation, e.g., by affecting cerebral perfusion.
D2 receptor binding also did not differ between baseline and
benserazide challenge and between L-DOPA/benserazide and
treatment with benserazide alone, showing that the effects of L-
DOPA on D2 receptor binding were not confounded by the joint
administration of the AADC inhibitor.
We admistered L-DOPA 30min prior to [123I]IBZM, and
SPECT measurements were performed from 75 to 135min
post-challenge. Since maximum striatal DA concentrations are
reached 40min after i.p. L-DOPA and remain stable for ∼2 h
(e.g., de Souza Silva et al., 1997), our D2 receptor binding data
were acquired during the maximum DAergic response. Changes
in of synaptic DA concentrations were estimated by multiplying
the percentual alteration of exogenous ligand binding with the
ratio of affinities (Kexo/Kendo), resulting in mean increases of DA
by 827 ± 361% after 5mg/kg and to 840 ± 161% after 10mg/kg
L-DOPA/benserazide. This order of magnitude is in agreement
with the increase of endogenous DA to 317% of baseline levels
observed 60min after 50mg/kg L-DOPA/benserazide in an
in vivo microdialysis study (de Souza Silva et al., 1997). The
increases in synaptic DA did not differ significantly between the
5 and 10mg/kg doses of L-DOPA/benserazide, indicating that
the 5mg/kg L-DOPA dose was sufficient to elicit maximum DA
release into the synaptic cleft.
Our results on D2 receptor binding are consistent with the
in vivo findings of Sossi et al. (2009) and Sahin et al. (2014),
who observed reductions of [11C]raclopride and [18F]fallypride
binding, respectively, relative to baseline in the degenerated
striatum of 6-OHDA lesioned rats. However, they are not
congruent with the results of Opacka-Juffry et al. (1998), who
observed an increased D2 receptor binding relative to untreated
controls in healthy rats. Moreover, they contradict the findings
of Hume et al. (1995), who reported an elevation of D2 receptor
binding in the lesioned striatum relative to the intact contralateral
side and to unlesioned rats and an increase in the unlesioned
striatum relative to healthy controls.
There is evidence that anesthetics may influence extracellular
DA levels (for review see Müller et al., 2011). Both ketamine—the
anesthetic used in the present investigation—and isoflurane—
the anesthetic employed by Hume et al. (1995), Opacka-Juffry
et al. (1998), Sossi et al. (2009), and Sahin et al. (2014)—have
been shown to enhance DA eﬄux (for review see Müller et al.,
2011). Thus, it may no be excluded that ketamine and isoflurance
contributed to the reduction of D2 receptor binding observed
in the present investigation as well as by Sossi et al. (2009) and
Sahin et al. (2014). Since Hume et al. (1995) and Opacka-Juffry
et al. (1998) also used isoflurance anesthesia, it may be ruled
out, however, that the discrepancy of findings was solely due to
anesthesia effects.
Yet, experimental procedures were widely discrepant: we
injected L-DOPA 30min prior to [123I]IBZM administration and
acquired static SPECT images from min 75 to min 135 post-
challenge; Sahin et al. (2014) also applied L-DOPA 30min prior
to [16F]fallypride but perfomed dynamic PET frommin 30 tomin
120 post-challenge; and Sossi et al. (2009) administerd L-DOPA
44min prior to [11C]raclopride and conducted dynamic PET
from min 45 to min 95 post-challenge, while Hume et al. (1995)
as well as Opacka-Juffry et al. (1998) administerd L-DOPA 90 and
100min, respectively, prior to [11C]raclopride and conducted
dynamic PET from min 90 to min 160, post-challenge. Thus, the
studies not only differed in the employed radioligands and the
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methods of data acquisition, but—more importantly—also in the
time windows post-challenge, during which D2 receptor imaging
data were acquired.
In vivo microdialysis studies have demonstrated that DA
molecules—practically immediately upon injection of L-DOPA—
start to accumulate in the synaptic cleft, reaching maximum
levels at about 60min post-challenge (e.g., de Souza Silva et al.,
1997). It is hypothesized that after entrance of the radiolabeled
molecules into the synaptic cleft, exgoneous and endogenous
ligands compete for D2 receptor binding sites. Apparently, this
may be visualized by the reduction of [123I]IBZM binding from
min 75 to min 135 post-challenge in the the present experiment,
as well as by the decrease of [18F]fallypride and [11C]raclopride
binding in the studies of Sahin et al. (2014) and Sossi et al. (2009),
which were observed from min 30 to min 120 and from min 45
to min 95 post-challenge, respectively.
Since a single application of L-DOPA elicits D2 receptor
mRNA expression in the neostriatum (Murata and Kanazawa,
1993), it is likely that the later initiation (90min post-challenge
relative to 30–75min post-challenge) of the imaging study by
Opacka-Juffry et al. (1998) provided sufficient time for the
development of D2 receptor sensitization. Striatal D2 receptor
supersensitivity also occurs in the unilateral 6-OHDA lesion
model (for review see Schwarting and Huston, 1996), and has
been demonstrated in vivo in both the lesioned and intact
contralateral hemisphere (Nikolaus et al., 2003). Thus, the
elevation of D2 receptor binding observed by Hume et al. (1995)
in the ipsilateral as well as contralateral striatum can be accounted
for by D2 receptor sensitization. In 6-OHDA lesioned rats, D2
receptor sensitization may occur as a compensatory response to
the decreased availability of DA in the lesioned and—to a lesser
extent—in the contralateral striatum. In healthy rats, however,
the increased availability of DA induced by L-DOPA may be
assumed to elicit a compensatory desensitization of D2 receptor
binding sites, leading to a lowered inhibitory input to the target
regions of DAergic neurons. DA is known to inhibit the release
of GABA via D2 receptor action (Girault et al., 1986), while
GABA, in turn, inhibits the release of DA (Grace and Bunney,
1979). Thus, decreased inhibitory input to GABAergic neurons is
likely to decrease striatal DA eﬄux, leading to a compensatory
upregulation of D2 receptor binding sites. Apparently, this
delayed effect of L-DOPA occurs when D2 receptor imaging is
initiated as late as 90min post-challenge, whereas the earlier
effect of L-DOPA is uncovered starting from 30 to 75min post-
challenge. It may be that in 6-OHDA-lesioned rats imaged in the
latter time window, the earlier L-DOPA effect normally leading
to a reduction of radioligand binding becomes partially masked
by the lesion-induced D2 receptor sensitization. This is evidenced
by the fact that the decrease of D2 receptor binding after L-DOPA
observed by Sahin et al. (2014) and Sossi et al. (2009) is one order
of magnitude lower compared to our findings.
Rat Behavior–Median Differences and t–b
Curves
Inspection of total time median values (Figures 5–9) show that
median ambulation frequency was lower and median sitting
duration was higher compared to saline after the higher L-DOPA
dose, while median duration and frequency of head-shoulder
motility were lower compared to saline after both L-DOPA doses.
These results are consistent with previous reports of reduced
behavioral activity after administration of the DA precursor
molecule in moderate doses to mature animals (McDevitt and
Setler, 1981; Grigoriadis et al., 1996).
The analysis of t–b curves (Figures 5–9) yielded significant
differences between (1) ambulation frequency after 10mg/kg L-
DOPA/benserazide and saline, (2) ambulation frequency after 10
and 5mg/kg L-DOPA/benserazide, (3) rearing frequency after 10
and 5mg/kg L-DOPA benserazide, (4) duration of head-shoulder
motility after 5mg/kg L-DOPA benserazide and saline, and,
finally, (5) frequency of head-shoulder motility after 10mg/kg
L-DOPA benserazide and saline. Thereby, ambulation frequency
curves yielded a higher rate constant after 10mg/kg L-DOPA
relative to both saline and the 5mg/kg dose, and a higher
plateau after 10mg/kg L-DOPA relative to 5mg/kg L-DOPA,
indicating a faster rate of decrease relative to saline, and a faster
rate of decrease to a higher final level relative to the lower L-
DOPA dose. Rearing frequency curves showed both a higher rate
constant and a higher plateau after 5 relative to 10mg/kg L-
DOPA, suggesting a higher rate of decrease to a higher final level
compared to the higher L-DOPA dose. Analysis of head-shoulder
motility duration curves yielded lower linear and quadratic terms
after 5mg/kg L-DOPA/benserazide relative to saline, indicating a
slower rate of decrease from a lower maximum level. Analysis of
head-shoulder motility frequency curves evidenced a lower slope
and a lower y-intercept after 10mg/kg L-DOPA/benserazide
relative to saline, which also suggests a slower rate of decrease
from a lower maximum level.
We use the method of fitting mathematical models to the
individual behavioral parameters, employing either linear or
non-linear regression analysis. The benefit of this approach is the
gaining of information on the temporal dynamics of behavior,
which is not achieved by the standard dose-response curves
relating changes in behavior merely to dose but not to time. In the
present study, the same mathematical models as in our previous
investigation (Nikolaus et al., 2014b) could be fit to the individual
behavioral parameters, which underlines the general suitability of
the t–b curve analysis approach.
The present results largely agree with our previous findings
on motor/exploratory behaviors after challenge with saline and
either 5 or 10mg/kg L-DOPA/benserazide. The most important
consistency is the finding of significantly reduced duration and
frequency of head-shoulder motility after both L-DOPA doses.
However, in the present study, the t–b curves of duration of
head-shoulder motility depicted no increase of behavior to the
maximum, but merely the subsequent decrease. Consequently,
we cannot infer a slower rate of increase in duration of
head-shoulder motility as found in the previous study, but,
instead, a slower rate of decrease from a lower maximum
level. t–b Curves of frequency of head-shoulder motility were
similar in both studies, showing a slower rate of decrease of
frequency of head-shoulder motility from a lower maximum
level.
The findings on frequency of ambulation also agree in
both studies, showing a significant reduction of ambulation
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frequency after the higher L-DOPA dose relative to saline. The
t–b curves of ambulation frequency were also similar in both
studies, indicating a faster rate of decrease after 10mg/kg L-
DOPA/benserazide relative to saline, and a faster rate of decrease
to a higher final level relative to the lower L-DOPA dose.
On the other hand, in the present study the effects of L-DOPA
on duration of sitting were less obvious. While in the previous
study a significantly higher sitting duration and faster rate of
increase of sitting duration to a higher final level was found after
both L-DOPA doses relative to saline, in the present study, a
significantly higher median sitting duration was merely observed
after the higher L-DOPA dose.
As in the previous study, the reduction of head-shoulder
motility after both L-DOPA doses relative to saline became
evident in the second time frame (min 6–10). But contrary
to the precedent results, significant decreases of ambulation
frequency as well as increases of sitting duration relative to
saline were detected already in the first time frame (min 1–5).
This coincides with the onset of measurable DA release, which
in in vivo microdialysis studies was observed already at the
moment of i.p. injection of L-DOPA/benserazide (de Souza Silva
et al., 1997), suggesting an association between the reduction
of motor/exploratory activity and the increased availability of
endogenous DA.
Taken together, also the present results show a time-dependent
decline of motor and exploratory behaviors in the open field. The
reduction of motor and exploratory activies such as ambulation
and head-shoulder motility over time is generally considered to
reflect behavioral habituation (for review see Leussis and Bolivar,
2006). Since these behavioral changes are likely to be related to
the L-DOPA-induced increase in endogenous DA, and DA is
known to be involved in learning and memory (for review see
Myhrer, 2003), the reduction in behavioral markers of activity
after L-DOPA, also in the present study might be due to its action
on the rate of behavioral habituation to a novel environment.
Correlation Analysis
After 5mg/kg L-DOPA/benserazide, D2 receptor binding
correlated negatively with sitting frequency (min 21–25). After
10mg/kg L-DOPA/benserazide, D2 receptor binding correlated
positively with the frequency of head-shoulder motility (min
1–30), grooming frequency (min 11–15, min 1–30), and sitting
duration (min 25–30).
Thus, lower D2 receptor binding was associated with a
decrease in exploratory behavior (head-shoulder motility) and
a decrease of grooming throughout the whole testing time, but
an increase in sitting frequency at the end of the trial. Since the
reduction of striatal D2 receptor binding after L-DOPA reflects
an increased availability of DA, it follows that a higher amount of
neostriatal DA decreased exploratory and grooming activity, but
facilitated sitting behavior, at least at the end of the trial, when,
interestingly, the animals sat down more often but in total for a
shorter time.
In our previous study (Nikolaus et al., 2014b), DAT
binding correlated negatively with sitting frequency (min
11–15), and positively with both duration and frequency
of head-shoulder motility (min 16–20) after 5mg/kg L-
DOPA/benserazide. Morever, in contrast to D2 receptor binding,
DAT binding correlated positively with duration (min 26–
30) and frequency (min 21–25) of rearing as well as with
duration of head-shoulder motility (min 21–25) after saline.
Since the reduction of striatal DAT binding after L-DOPA can
be assumed to reflect increased availability of DA, it may be
conjectured—in analogy to the results obtained by D2 receptor
imaging—that a higher amount of neostriatal DA decreased
motor/exploratory behaviors and facilitated sitting. Strikingly,
however, DAT imaging in contrast to D2 receptor imaging
implies that this relation holds for both L-DOPA and saline.
If striatal DA levels rise, more DA molecules may bind
to striatal D2 receptors (leading to a reduction of [
123I]IBZM
binding). Concomitantly, free DA is transported back into
the presynaptic terminal via DAT binding sites (leading
to the reduction of [123I]FP-CIT binding in the precedent
investigation). Apparently, with the [123I]FP-CIT-DAT imaging
approach, the association between behavior and DA molecules
binding to the DAT can be already detected, when DA is not
supposed to rise beyond “normal” levels as is the case after pre-
treatment with saline. This is not the case with the [123I]IBZM-D2
receptor imaging approach.
[123I]IBZM-SPECT does not allow to differentiate between
D2 autoreceptor and D2 heteroreceptor binding sites. If DA
levels rise, DA molecules bind to either site reducing the
possibility of both pre- and postsynaptic receptor binding for
[123I]IBZM. The critical issue, however, appears to be that
DA not only triggers feedback inhibition at the presynaptic
D2 autoreceptor binding sites and desensitizises postsynaptic
D2 heteroreceptors, but—in response to the D2 autoreceptor-
induced reduction of DA release—also leads to a renewed
sensitization of postsynaptic binding sites. Possibly, the renewed
sensitization of postsynaptic D2 receptors binding sites hampers
the visualization of altered [123I]IBZM binding in relation to
alterations of motor/exploratory behaviors, if DA levels are
within the “normal” range. If this range is exceeded, as may
be assumed for L-DOPA challenge, the balance between DA
concentration and receptor regulation state is likely to become
unhinged, and the increased availability of DA—in the given time
window—can no longer be masked by the upregulation of D2
receptor binding sites.
Furthermore, it is interesting that motor/exploratoy behaviors
are correlated with D2 receptor binding after both L-DOPA
doses, whereas no correlations were observed between
motor/exploratory behaviors and DAT binding after 10mg/kg.
A previous study had indicated a biphasic action of L-DOPA
with a higher effect on DAT after the lower dose of L-DOPA
(Nikolaus et al., 2013). It may be that DA concentrations
after 10mg/kg L-DOPA at the time between application and
equilibration of [123I]FP-CIT were lower compared to the
5mg/kg dose, because the higher dose may have promoted the
release of DA in concentrations sufficient to activate feedback
inhibition at the presynaptic terminal. The shorter time span
between the application of L-DOPA and the equilibration of
the D2 receptor radioligand may have precluded the occurrence
of biphasic actions in the [123I]IBZM-D2 receptor imaging
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approach. Further investigations are needed, which explicitly
address the issue of suitability of either approach in terms of both
L-DOPA dosage and time between pharmacological challenge
and initiation of SPECT data acquisition.
CONCLUSIONS
The present complementary investigation of D2 receptor
binding and behavioral parameters yielded reductions of striatal
D2 receptor binding after L-DOPA, which reflect increased
availability of endogenous DA. As L-DOPA-treated animals
displayed less ambulation, less head-shoulder motility and more
sitting than saline-treated animals, it may be assumed that the
decrease of behavioral activity is associated with the increased
availibility of DA.
The analysis of t–b curves for ambulation frequency evidenced
a faster rate of decrease after 10mg/kg L-DOPA/benserazide
relative to saline, and a faster rate of decrease to a higher final level
relative to the lower L-DOPA dose. Rearing frequency curves
yielded a higher rate of decrease to a higher final level after
5mg/kg L-DOPA/benserazide compared to the higher L-DOPA
dose. Analysis of t–b curves for both duration and frequency
of head-shoulder motility indicated a slower rate of decrease of
duration and frequency of motility from a lower maximum level
after 5mg/kg and 10mg/kg L-DOPA/benserazide, respectively,
relative to saline. Our results largely agree with previous
findings (Nikolaus et al., 2014b) and suggest that decline of
behavioral markers of activity after L-DOPA may be due to
its action on the rate of behavioral habituation to a novel
environment. The moderate association between D2 receptor
binding and parameters of motor and exploratory behavior
as evidenced by correlation analysis is in agreement with
previous evidence on the relevance of brain regions beyond
the neostriatum (such as the hippocampus and the prefrontal
cortex) for the unfolding of central L-DOPA action (Navailles
et al., 2010). It is also consistent with the role assigned to
neurotransmitters beyond DA (such as serotonin, acetylcholine,
and glutamate) for motor activity as well as habituation learning
(e.g., Dringenberg et al., 1995; Carey et al., 1998; Schildein et al.,
2002).
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